← Back to Clinical Trials
Recruiting NCT06070467

NCT06070467 Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06070467
Status Recruiting
Phase
Sponsor University Hospital, Strasbourg, France
Condition Eye Diseases
Study Type OBSERVATIONAL
Enrollment 154 participants
Start Date 2024-07-17
Primary Completion 2026-07

Eligibility & Interventions

Sex All sexes
Min Age 8 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Mixed Methods Research (MMR) using quantitative (QUAN) and qualitative (QUAL) tools

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 154 participants in total. It began in 2024-07-17 with a primary completion date of 2026-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Rare Eye Diseases (RED) are the leading cause of severe visual impairment/ blindness (SVI/B) in children in Europe. This sensory disability with its accompanying psychological distress hugely impacts their lives and their families. Understanding this impact, at a patient centred level, is key in care, in shared decision making, in developing therapies, and in improving social integration and participation about the standard rules of the United Nations (UN) and the European Union (EU) (prevention, non-discrimination, equal opportunities, accessibility, etc.). However, current tools to evaluate vision related (VR) quality of life (QoL) VR-QoL disregard age and cultural differences. There is a lack knowledge on how the disease matters at child's level. Instruments capable of yielding high-quality data, psychometrically robust and comply with regulatory requirements remain to be developed. To fill this gap, SeeMyLife will use multilevel concurrent mixed method research combining quantitative studies and qualitative studies. The quantitative approach is based on (i) cross culturally translated validated VR-QoL questionnaires for children and teenagers (Functional Vision Questionnaire for Children and Young People - FVQ-CYP and Vision-related Quality of Life Questionnaire for Children and Young People - VQoL-CYP) and (ii) on caregiver's questionnaires addressing participation and environment (Participation and Environment Measure - Children and Youth - PEM-CY). To fully capture the picture of the child/teenager personal life the investigators will reinforce their investigations by in depth qualitative socio-anthropologic study with semi directive field interviews and fieldwork (to observe closely the living conditions of the children) to address how their impairment affects their wellbeing, social integration, and how they feel about medical and social interventions. Data analysis will use an integrated mixed method strategy to validate the quantitative tools and deliver a holistic QoL transnational tool. The SeeMyLife project will provide (i) robust patient self-reported tools that will be then used in care and research (especially with the rise in novel therapies) as a standard as well as (ii) highly awaited knowledge about the SVI/B patient's position within his own life course, within his family and in relation to health and social care actors.

Eligibility Criteria

Inclusion Criteria: * Children (age 8-12) and teenagers (age 13-18) with various levels of visual impairment defined according to World Health Organization (WHO) International Classification of Diseases (ICD) 10 - WHO ICD 10 \[best-corrected visual acuity ≤ 0.3 decimal or ≤ 6/18\], and their parents/caregivers. Exclusion Criteria: * Children, teenagers, and caregivers: 1. who lack the ability to respond in a reliable way to the questions on how they feel about their visual impairment (patients with mild intellectual or cognitive deficiency may be able to reply accurately as opposed to cases with severe intellectual disability) 2. with functional or non-ophthalmic reasons of visual impairment 3. unable to provide consent/assent; 4. who do not speak/read the language

Frequently Asked Questions

Who can join the NCT06070467 clinical trial?

This trial is open to participants of all sexes, aged 8 Years or older, studying Eye Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06070467 currently recruiting?

Yes, NCT06070467 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital, Strasbourg, France to inquire about joining.

Where is the NCT06070467 trial being conducted?

This trial is being conducted at Strasbourg, France.

Who is sponsoring the NCT06070467 clinical trial?

NCT06070467 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 154 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology